Redx Pharma identifies drug development candidate for leukaemia program
Redx Pharma has identified a drug development candidate for its reversible Bruton’s Tyrosine Kinase (BTK) inhibitor program.
The compound, named RXC005, has the potential to treat the majority of patients suffering from Chronic Lymphocytic Leukaemia (CLL), including those who become resistant to the increasingly used treatment Ibrutinib.
